Full data announced in phase III EMPA-KIDNEY trial
The EMPA-KIDNEY phase III clinical trial met its primary endpoint by demonstrating a significant kidney and cardiovascular benefit for adults living with chronic kidney disease (CKD)
Alexandra Breiner, a Senior Communications Manager in Corporate Affairs, highlights her career and the many development programmes at Boehringer Ingelheim.
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.